PeptideScanner corrections, routine public-version updates, and source-published research-integrity notices remain separate. Earlier public versions remain available rather than being silently erased.
Material record
Corrections and retractions
Factual errors, withdrawals, and retractions appear here separately from routine wording or source updates.
We refreshed this profile's label citation to the reviewed SPL version 19, published 2026-08-17. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Profile summary
Before
A peptide named in FDA compounding-risk and DOJ enforcement records.
After
FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.
Evidence note
Before
FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.
After
FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.
We refreshed this profile's label citation to the reviewed SPL version 62, published 2026-08-10. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
The previous profile described elamipretide only as investigational. We added FDA's September 19, 2025 accelerated approval of Forzinity for the specified Barth syndrome population. This correction does not extend that approval to other uses or formulations.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
Investigational
After
U.S. accelerated approval for a specified Barth syndrome population
Status classification
Before
investigational
After
approved
Profile summary
Before
A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.
After
FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
Evidence note
Before
ClinicalTrials.gov lists the 4TAZPower study as recruiting, updated July 13, 2026.
After
FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's emideltide briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates Emideltide-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's Epitalon briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates epitalon free base and acetate and distinguishes the tetrapeptide from epithalamin, a pineal-gland extract. The briefing is an advisory-process assessment, not a final regulatory determination.
The previous summary described this only as an emergency-treatment label. We now distinguish Gvoke's severe-hypoglycemia indication from Gvoke VialDx's diagnostic indication in the same cited label.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Profile summary
Before
A peptide hormone. This profile cites a U.S. emergency-treatment label.
After
A peptide hormone. The cited U.S. label distinguishes Gvoke for severe hypoglycemia from Gvoke VialDx for diagnostic use.
Evidence note
Before
The cited DailyMed label identifies Glucagon and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The cited label describes subcutaneous Gvoke for severe hypoglycemia in people with diabetes aged two years and older, and intravenous Gvoke VialDx as a diagnostic aid in adults. The product, route and indication must remain distinct.
We added FDA's dated assessment to distinguish substance forms, evaluated uses and the advisory stage of review. Earlier profile versions remain available.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Profile summary
Before
A peptide named in FDA compounding-risk and DOJ enforcement records.
After
FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.
Evidence note
Before
FDA's compounding-risk page describes immunogenicity and characterization concerns. A separate Justice Department release names Ipamorelin among unapproved new drugs distributed by the cited pharmacy.
After
At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's KPV briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates KPV-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
The previous profile used an unqualified investigational status. We added dated local-government reports of approval in China while keeping national decision and label verification open. Earlier trial-based versions remain available.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
Investigational
After
China: approval reported by local government sources
Status classification
Before
investigational
After
approval-reported
Profile summary
Before
A metabolic peptide candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
After
A June 2025 Suzhou Industrial Park regulator report describes Chinese approval of mazdutide injection for long-term weight management in adults with obesity or overweight. A December 2025 Suzhou government report describes approved diabetes and weight-management indications in China.
Evidence note
Before
ClinicalTrials.gov lists a West China Hospital study as not yet recruiting, updated July 21, 2026.
After
These are attributable local-government reports, not the national approval decision or complete prescribing information. The national decision and exact indication conditions remain to be reconciled. This account does not establish approval in the United States or other jurisdictions.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates MOTS-c-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's Semax briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates Semax-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
After
FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We refreshed this profile's label citation to the reviewed SPL version 9, published 2026-07-31. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
We refreshed this profile's label citation to the reviewed SPL version 40, published 2026-09-02. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
These entries preserve wording changes or ordinary source-record updates. An entry here does not by itself mean the earlier version contained a factual error.
We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.
PeptideScanner change date
July 29, 2026
Evidence lane
Profile
Status
Before
FDA identity record only; approval status not established
After
FDA compounding safety review; final determination pending
Status classification
Before
identity-only
After
safety-review
Topic
Before
Identity records
After
Safety records
Profile summary
Before
A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.
After
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
Evidence note
Before
FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.
After
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications.
PeptideScanner change date
July 29, 2026
Evidence lane
Profile
Profile summary
Before
A research peptide with FDA compounding records and a recent trial-registry entry.
After
A research peptide represented by FDA compounding-review material and one selected trial-registry record.
Evidence note
Before
FDA's 2026 briefing says BPC-157 is not a component of an FDA-approved drug and describes limited safety information and characterization concerns. ClinicalTrials.gov also lists a recruiting study; registration is not proof of effectiveness.
After
FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.
We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review.
PeptideScanner change date
July 29, 2026
Evidence lane
Profile
Profile summary
Before
A mitochondrial-derived peptide included in an FDA compounding-risk record.
After
A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.
Evidence note
Before
FDA's compounding-risk page says it has not identified human exposure data for drug products containing MOTS-c and lacks important safety information.
After
FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
These publisher or Retraction Watch notices are registered in the reviewed Crossref snapshot for a publication used in supervised synthesis. They are not PeptideScanner corrections and do not silently alter the preserved synthesis wording.
Crossref connects notice DOI 10.1016/s0140-6736(21)01556-7 ↗ to publication DOI 10.1016/s0140-6736(21)01324-6. Registered July 17, 2021.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1016/s2213-8587(26)00157-9 ↗ to publication DOI 10.1016/s2213-8587(26)00125-7. Registered June 19, 2026 and August 1, 2026.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1016/s2213-8587(25)00399-7 ↗ to publication DOI 10.1016/s2213-8587(23)00356-x. Registered December 17, 2025 and February 1, 2026.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1038/s41591-026-04650-w ↗ to publication DOI 10.1038/s41591-026-04479-3. Registered August 25, 2026.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1016/s2213-8587(22)00051-1 ↗ to publication DOI 10.1016/s2213-8587(21)00296-5. Registered March 1, 2022.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1016/s2213-8587(22)00360-6 ↗ to publication DOI 10.1016/s2213-8587(22)00277-7. Registered February 1, 2023.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
How version history works
PeptideScanner checks the cited record, preserves the earlier public version, and publishes a dated notice explaining the change. A factual correction identifies the error and supporting source; a routine update is labeled separately. Every published revision above comes from the same deterministic before-and-after ledger used by the profile and recent-change pages.
Representatives from GoodSir Labs publish and review PeptideScanner. PeptideScanner does not yet publish a dedicated reporting channel. A verified organization-level route will appear here before the site invites submissions; no personal contact details are exposed in the meantime.